Perinatal HIV-1 transmission -: Interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort

被引:201
|
作者
Mandelbrot, L
Le Chenadec, J
Berrebi, A
Bongain, M
Bénifla, JL
Delfraissy, JF
Blanche, S
Mayaux, MJ
机构
[1] Hop Cochin Port Royal, Serv Gynecol Obstet 1, F-75014 Paris, France
[2] INSERM, U149, Paris, France
[3] INSERM, U292, Le Kremlin Bicetre, France
[4] Hop La Grave, Serv Gynecol Obstet, Toulouse, France
[5] Hop Archet 2, Serv Gynecol Obstet, Nice, France
[6] Hop Bichat Claude Bernard, Serv Gynecol Obstet, F-75877 Paris, France
[7] Hop Kremlin Bicetre, Serv Med Interne, Le Kremlin Bicetre, France
[8] Hop Necker Enfants Malad, Serv Pediat, Paris, France
来源
关键词
D O I
10.1001/jama.280.1.55
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context.-It is unclear whether elective cesarean delivery may have a protective effect against the transmission of human immunodeficiency virus 1 (HIV-1). Objective.-To investigate whether mode of delivery has an impact on perinatal HIV-1 transmission in the presence of zidovudine prophylaxis. Design.-A prospective cohort study. Setting.-The 85 perinatal centers in the French Perinatal Cohort, from 1985 to 1996. Patients.-A total of 2834 singleton children born to mothers with HIV-1 infection. Main Outcome Measure.-Human immunodeficiency virus 1 infection of the infant. Results.-No zidovudine was used in 1917 pregnancies and zidovudine prophylaxis was used in 902 pregnancies. Cesarean deliveries were performed in 10.9% on an emergent basis and in 8.3% electively, prior to labor or membrane rupture. In 1917 mothers who did not receive zidovudine, of 1877 with information on mode of delivery, 17.2% transmitted HIV-1 to their child. Risk factors statistically significantly associated with transmission were maternal p24 antigenemia, cervicovaginal infections during pregnancy, amniotic fluid color, and rupture of membranes 4 hours or more before delivery. Mode of delivery was not related to transmission. in 902 mothers receiving zidovudine, transmission was 6.4% in 872 with information on mode of delivery, and elective cesarean delivery (n = 133) was associated with a lower transmission rate than emergent cesarean or vaginal delivery (0.8%, 11.4%, and 6.6%, respectively; P=.002). In a multivariate analysis of all mother-child pairs, including obstetrical risk factors, maternal p24 antigenemia, and zidovudine prophylaxis, interaction between mode of delivery and zidovudine prophylaxis was significant (P=.007). In the multivariate analysis of pregnancies with zidovudine prophylaxis, factors related to transmission rate were maternal p24 antigenemia, amniotic fluid color, and mode of delivery. Adjusted odds ratios (95% confidence intervals) were 1.6 (0.7-3.6) for emergent cesarean delivery and 0.2 (0.0-0.9) for elective cesarean delivery (P =.04) in comparison with vaginal delivery. Conclusions.-We observed an interaction between zidovudine prophylaxis and elective cesarean delivery in decreasing transmission of HIV-1 from mother to child. This observation may have clinical implications for prevention.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 50 条
  • [1] Zidovudine prophylaxis and perinatal HIV-1 transmission
    Zuccotti, GV
    Ferraris, G
    Agostoni, C
    Rancilio, L
    Ravizza, M
    Bucceri, AM
    Riva, E
    Marini, A
    [J]. ACTA PAEDIATRICA, 1999, 88 (11) : 1298 - 1298
  • [2] Mode of delivery and gestational age influence perinatal HIV-1 transmission
    Tovo, PA
    deMartino, M
    Gabiano, C
    Galli, L
    Cappello, N
    Ruga, E
    Tulisso, S
    Vierucci, A
    Loy, A
    Zuccotti, GV
    Bucceri, AM
    Plebani, A
    Marchisio, P
    Caselli, D
    Liviadotti, S
    Dallacasa, P
    Fundaro, C
    Stegagno, M
    Timpano, C
    Ruggeri, M
    Duse, M
    Belloni, M
    Cocchi, P
    Risso, S
    Forni, GL
    Lipreri, R
    Ciccimarra, F
    Consolini, R
    Benaglia, G
    Caramia, G
    DeSantis, U
    Chiriaco, PG
    Dessi, C
    Ibba, P
    Zannino, L
    DiGregorio, F
    Sciotto, A
    Cecchi, MT
    Boeri, E
    Meo, A
    Magni, LA
    Altobelli, R
    Contardi, I
    Gambaretto, G
    Esposito, L
    Bona, G
    Giordano, S
    Ragazzini, I
    Magnani, C
    Bionda, S
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 11 (01): : 88 - 94
  • [3] Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load
    Golden, B
    Cooper, E
    Cundall, D
    Moy, R
    [J]. LANCET, 1999, 354 (9173): : 158 - 159
  • [4] Perinatal transmission of HIV-1
    Asakura, Y
    Mohri, H
    Okuda, K
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (16): : 1300 - 1300
  • [5] ZIDOVUDINE AND PREVENTION OF PERINATAL HIV TRANSMISSION
    LEGG, JJ
    GOLDSCHMIDT, RH
    [J]. AMERICAN FAMILY PHYSICIAN, 1995, 52 (03) : 745 - &
  • [6] Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load - Reply
    Shaffer, N
    Siriwasin, W
    Bhadrakom, C
    Chotplayasunondh, T
    Chearskul, S
    [J]. LANCET, 1999, 354 (9173): : 157 - 158
  • [7] Determinants of perinatal HIV-1 transmission
    Orloff, SL
    Simonds, RJ
    Steketee, RW
    StLouis, ME
    [J]. CLINICAL OBSTETRICS AND GYNECOLOGY, 1996, 39 (02): : 386 - 395
  • [8] Perinatal transmission of HIV-1 - Reply
    Dickover, R
    Bryson, Y
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (16): : 1301 - 1301
  • [9] Effect of perinatal zidovudine prophylaxis on the evolution of cell-free HIV-1 RNA in breast milk and on postnatal transmission
    Manigart, O
    Crépin, M
    Leroy, V
    Meda, N
    Valéa, D
    Janoff, EN
    Rouet, F
    Dequae-Merchadoux, L
    Dabis, F
    Rouzioux, C
    Van de Perre, P
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (08): : 1422 - 1428
  • [10] Zidovudine genotypic resistance in HIV-1-infected newborns in the French Perinatal Cohort
    Masquelier, B
    Chaix, ML
    Burgard, M
    Lechenadec, J
    Doussin, A
    Simon, F
    Cottalorda, J
    Izopet, J
    Tamalet, C
    Douard, D
    Fleury, H
    Mayaux, MJ
    Blanche, S
    Rouzioux, C
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 27 (02): : 99 - 104